MEND-CABG II: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Cardioprotective Effects of MC-1 in Patients Undergoing High-Risk CABG Surgery

NCT00402506 Phase 3 COMPLETED

The purpose of this study is to determine the effect of MC-1 on the combined incidence of cardiovascular death and nonfatal myocardial infarction (MI) up to and including 30 days following coronary artery bypass graft (CABG) surgery compared with placebo.

Details

Lead sponsor	Medicure
Phase	Phase 3
Status	COMPLETED
Enrolment	3000
Start date	2006-11
Completion	2007-09

Conditions

• Coronary Artery Bypass Graft Surgery
• Myocardial Ischemia
• Reperfusion Injury

Interventions

• (MC-1) Pyridoxal 5'-phosphate

Primary outcomes

• combined incidence of cardiovascular death or nonfatal myocardial infarction on days up to and including post-operative day (POD) 30

Countries

United States, Canada